These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22670016)

  • 1. GRP78, intronic polymorphisms, and pharmacogenomics in non-small cell lung cancer.
    Merrick DT
    Chest; 2012 Jun; 141(6):1377-1378. PubMed ID: 22670016
    [No Abstract]   [Full Text] [Related]  

  • 2. Intronic boundary mutation rs430397 cannot affect alternate splicing and is an indecisive risk factor for non-small cell lung cancer.
    Zhu X; Fan W; Li D
    Chest; 2012 Dec; 142(6):1691-1692. PubMed ID: 23208355
    [No Abstract]   [Full Text] [Related]  

  • 3. An intronic polymorphism in GRP78 improves chemotherapeutic prediction in non-small cell lung cancer.
    Zhu X; Lin MCM; Fan W; Tian L; Wang J; Ng SS; Wang M; Kung H; Li D
    Chest; 2012 Jun; 141(6):1466-1472. PubMed ID: 21940774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-199a-5p and miR-495 target GRP78 within UPR pathway of lung cancer.
    Ahmadi A; Khansarinejad B; Hosseinkhani S; Ghanei M; Mowla SJ
    Gene; 2017 Jul; 620():15-22. PubMed ID: 28363780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Afatinib Treatment in Non-small Cell Lung Cancer Cells.
    Pancewicz-Wojtkiewicz J; Bernatowicz PL
    Anticancer Res; 2017 Jul; 37(7):3543-3546. PubMed ID: 28668844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversed expression of GRIM-1 and GRP78 in human non-small cell lung cancer.
    Wu HM; Jiang ZF; Fan XY; Wang T; Ke-Xu ; Yan XB; Ma Y; Xiao WH; Liu RY
    Hum Pathol; 2014 Sep; 45(9):1936-43. PubMed ID: 25081541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intronic polymorphism (1541-1542delGT) of the constitutive heat shock protein 70 gene has functional significance and shows evidence of association with lung cancer risk.
    Rusin M; Zientek H; Krześniak M; Małusecka E; Zborek A; Krzyzowska-Gruca S; Butkiewicz D; Vaitiekunaite R; Lisowska K; Grzybowska E; Krawczyk Z
    Mol Carcinog; 2004 Mar; 39(3):155-63. PubMed ID: 14991745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine.
    Yin JY; Li X; Zhou HH; Liu ZQ
    Pharmacogenomics; 2016 Aug; 17(12):1365-78. PubMed ID: 27462924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.
    Xiang T; Kang X; Gong Z; Bai W; Chen C; Zhang W
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):791-800. PubMed ID: 28314991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients.
    Nogueira A; Assis J; Catarino R; Medeiros R
    Pharmacogenomics; 2013 Apr; 14(6):689-700. PubMed ID: 23570471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim.
    Couzin J
    Science; 2004 Aug; 305(5688):1222-3. PubMed ID: 15333809
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems.
    Xiong Y; Huang BY; Yin JY
    Med Oncol; 2017 Apr; 34(4):48. PubMed ID: 28215024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.
    Araújo A; Ribeiro R; Azevedo I; Coelho A; Soares M; Sousa B; Pinto D; Lopes C; Medeiros R; Scagliotti GV
    Oncologist; 2007 Feb; 12(2):201-10. PubMed ID: 17296816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward therapies tailored to patient characteristics.
    Novello S; Longo M; Levra MG
    J Thorac Oncol; 2007 May; 2(5 Suppl):S38-41. PubMed ID: 17457231
    [No Abstract]   [Full Text] [Related]  

  • 15. Heat Shock Proteins in Non-Small-Cell Lung Cancer-Functional Mechanism.
    Zhou G; Pu Y; Zhao K; Chen Y; Zhang G
    Front Biosci (Landmark Ed); 2023 Mar; 28(3):56. PubMed ID: 37005758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Genomic approaches to tailored therapy in non-small cell lung cancer].
    Song Y
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Dec; 31(12):889-90. PubMed ID: 19134403
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of XRCC1 gene polymorphisms in non-small cell lung cancer cisplatin-based chemotherapy, and their effect on clinical and pathological characteristics.
    Liu HF; Liu JS; Deng JH; Wu RR
    Genet Mol Res; 2016 Dec; 15(4):. PubMed ID: 28081275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
    Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
    J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms and non-small-cell lung cancer: future paradigms.
    de Mello RA
    Einstein (Sao Paulo); 2014; 12(4):524-6. PubMed ID: 25628210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
    Buikhuisen WA; Burgers JA; Vincent AD; Schellens JH; Beijnen JH; Smit EF; Joerger M
    J Clin Oncol; 2010 Sep; 28(27):e482-3; author reply e484. PubMed ID: 20606096
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.